Clarithromycin resistance in Helicobacter pylori and its clinical relevance

Table 1 Effect of primary clarithromycin resistance on the efficacy of eradication therapy for Helicobacter pylori infection

Authors	Treatment regimens	Eradication rate (%)		Prevalence of resistant strains post-treatment (%)*
		Susceptible strains	Resistant strains
Liu et al[5] 1996	LFC or BFC	98 (45/46)	0 (0/4)	100 (5/5)
Suzuki et al[8] 1998	LAC	94 (66/70)	0 (0/1)	40 (2/5)
Miyaji et al[9] 1997	OC or LC	64 (9/14)	0 (0/5)	80 (20/25)
	OAC or LAC	85 (57/67)	28 (2/7)	(Overall)
	OCM or LCM	86 (68/79)	38 (3/8)
Maeda et al[10] 1998	LAC	85 (29/34)	40 (2/5)	63 (5/8)
Megraud et al[13] 1997	OC	70 (33/47)	38 (3/8)	81 (17/21)
	RbCC	98 (42/43)	92 (11/12)	(Overall)
Debets-Ossenkopp et al[16] 1996	RC	81 (58/72)	0 (0/1)	73 (11/15)
Tompkins et al[18] 1997	OC	80 (101/127)	0 (0/4)	74 (14/19)
Moayyedi et al[19] 1998	OCT	91 (104/114)	40 (2/5)	Nor reported
Schutze et al[24] 1996	RC	75 (21/28)	20 (1/5)	91 (10/11)
Laine et al[25] 1998	AC	35 (73/208)	7.7 (2/2.6)	53 (70/131)
	OAC	81 (153/190)	27 (4/15)	(Overall)
Yousfi et al[26] 1996	RanMC	87 (20/23)	25 (1/4)	67 (4/6)
Buckley et al[46] 1997	OMC	85 (71/84)	0 (0/3)	58 (7/12)

O, omeprazole; C, clarithromycin; A, amoxycillin; Ran, ranitidine; M, metronidazole; Rbc, ranitidine bismuth citrate; L, lansoprazole; Rox, Roxithromycin; B, colloidal bismuth subcitrate (CBS). *The number of resistant strains post treatment was greater than the numbe r of resistant strains before treatment in all the studies, suggesting acquisiti on of clarithromycin resistance during the unsuccessful treatment.